OFX
0.805
69.5%
ARO
0.003
-25%
PER
0.003
50%
CAN
0.003
-25%
PGO
0.15
40.2%
MNB
0.019
-20.8%
IOV
0.455
37.9%
RAN
0.17
-19%
GDG
4.58
37.1%
BUX
0.04
-18.4%
ECT
0.135
28.6%
RRR
0.058
-17.1%
THR
0.009
28.6%
AUA
0.032
-15.8%
SLB
0.205
24.2%
TRP
0.08
-15.8%
AU1
0.027
22.7%
FTI
0.53
-14.5%
EV1
0.011
22.2%
ADN
0.006
-14.3%
NVU
0.055
22.2%
M4M
0.006
-14.3%
PTX
0.094
20.5%
PL9
0.006
-14.3%
MVL
0.012
20%
TAR
0.02
-13%
GW1
0.087
19.2%
CF1
0.028
-12.5%
EG1
0.026
18.2%
MRZ
0.105
-12.5%
KPO
0.02
17.6%
OVT
0.007
-12.5%
POD
0.04
17.6%
ZEU
0.007
-12.5%
PPL
0.034
17.2%
AXQ
3.52
-12%
OCN
0.415
16.9%
BOA
0.052
-11.9%
H3E
0.007
16.7%
SKO
1.06
-11.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf